Clinical Trial Update: Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three combinations of docetaxel and irinotecan in patients with recurrent or metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Taxotere (docetaxel)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED